Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNP6T3)

• Drug Name: GEN1042 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMNP6T3

Molecule-Related Drug Atlas

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[3]
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[4]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[5]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[3]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[6]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[7]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[8]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[9]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[10]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[11]

Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urelumab	DM6RTVG	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[4]
Anti-CD137	DMHVZ27	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
MG7-CART	DME6PB0	Acute myeloid leukaemia	2A60	Phase 1/2	[13]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[14]
CD137 CAR-T Cell	DMHMC19	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[15]
ADG106	DM87H0S	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[16]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[17]
MCLA-145	DM8CGUV	Lymphoma	2A80-2A86	Phase 1	[18]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Agonist	[2]
Co-stimulatory molecule 4-1BB (CD137)	TTPW9LJ	TNR9_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT04083599) GEN1042 Safety Trial in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Genmab.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [6] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [7] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [8] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [9] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [10] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Shattuck Labs.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [13] ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
• [14] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [15] ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
• [16] Clinical pipeline report, company report or official report of Adagene.
• [17] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [18] Clinical pipeline report, company report or official report of Merus.
• [19] Clinical pipeline report, company report or official report of Inhibrx.